Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs
跨人群与研究设计比较 HIV 疫苗免疫原性
Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double-blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time-consuming, and/or logistically challenging. These challenges lead to a great interest in immune responses induced by vaccination, and in identifying which immune responses predict…